KN0.F Dicot Pharma AB
- Market cap
- EUR 45.1M
- P/E
- -
- P/B
- 2.30x
- ROE
- -33.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KN0.F undervalued?
Graham numberThe Graham number of Dicot Pharma AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dicot Pharma AB fundamental analysis
No fundamental analysis for Dicot Pharma AB yet.
Dicot Pharma AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dicot Pharma AB
Dicot Pharma AB (publ) engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB (publ) in May 2024. Dicot Pharma AB (publ) was incorporated in 2015 and is based in Uppsala, Sweden.
Full company profileDicot Pharma AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dicot Pharma AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -27.3M | -31.8M | -45.0M | -59.3M | -82.6M | -79.7M |
| EBITDA | - | -31.7M | -44.1M | -57.7M | -80.2M | -77.9M |
| Net Income | -27.2M | -31.8M | -44.2M | -57.7M | -80.2M | -77.9M |
| EPS | -0.13 | -0.10 | -0.04 | -0.03 | -0.04 | -0.02 |
| Balance Sheet | ||||||
| Total Assets | 31.8M | 12.4M | 53.6M | 124M | 85.5M | 239M |
| Total Liabilities | 3.42M | 7.01M | 9.16M | 12.0M | 12.1M | 8.70M |
| Shareholders' Equity | 28.4M | 5.36M | 44.4M | 112M | 73.4M | 230M |
| Cash & Short-term Investments | 30.3M | 9.38M | 47.3M | 113M | 69.2M | 226M |
| Cash Flow | ||||||
| Operating Cash Flow | -25.9M | -29.7M | -45.2M | -58.9M | -85.9M | -77.2M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 933K |
| Free Cash Flow | -25.9M | -29.7M | -45.2M | -58.9M | -85.9M | -78.1M |
| Ratios | ||||||
| ROE | -95.9% | -592.7% | -99.5% | -51.7% | -109.4% | -33.8% |
| ROA | -85.5% | -256.7% | -82.5% | -46.7% | -93.9% | -32.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Dicot Pharma AB dividends
Dicot Pharma AB has not paid dividends in the last 5 fiscal years.
Who owns Dicot Pharma AB
- Insiders 10.32%
- Institutions 15.67%
- Public & others 74.01%
- Shares outstanding 3.47B
- Free float 3.19B
Dicot Pharma AB company profile
- Company name
- Dicot Pharma AB
- Ticker
- KN0.F
- ISIN
- SE0011178458
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 4
- Fiscal year end
- December
- Address
- S:t Olofsgatan 11A, Uppsala, Sweden, 753 21
- Phone
- 46 7 25 02 10 10
- Website
- dicotpharma.com
About Dicot Pharma AB
Dicot Pharma AB (publ) engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB (publ) in May 2024. Dicot Pharma AB (publ) was incorporated in 2015 and is based in Uppsala, Sweden.
Dicot Pharma AB management
6- Ms. Elin TrampeChief Executive Officer · born 1980
- Dr. Jarl Wikberg Ph.D.Founder
- Ms. Cecilia DrivingChief Financial Officer · born 1971
- Dr. Mats Silvander Ph.D.Chief Technical Officer
- Ms. Charlotta GauffinChief Scientific Officer · born 1971
- Mr. Hakan WickholmChief Business Officer · born 1959